Home>Topics>Companies>Baxter International

Baxter International BAX

  1. All
  2. Commentary
  3. Video Reports
  4. Headlines
    1. Fitch Downgrades Baxter International Inc . to 'BBB+'; Outlook Stable

      Headlines

      Fri, 29 May 2015

      May 29 (Fitch) Fitch Ratings has downgraded Baxter International Inc .'s ( Baxter ) long-term Issuer Default Rating (IDR) by ..... company's short-term IDR to 'F2' from 'F1'. Baxter had approximately $10 billion in outstanding debt

    2. Baxter's Spin-Off Strategy Is Promising

      Video Reports

      Wed, 27 May 2015

      Karen Andersen: Baxter ( BAX ) is a diversified health-care company ..... to think about the future of the new Baxter , as it is planning to spin off its bioscience ..... continue to have economic moats. The new Baxter sees cost advantages as it is part of

      BAX found at 0:04

      Karen Andersen:  Baxter ( BAX ) is a diversified health-care company that currently holds a 4-star rating and is trading at about a 15% discount to our fair
    3. UPDATE 1-Novo Nordisk, Baxter clash over haemophilia drug patent

      Headlines

      Wed, 20 May 2015

      COPENHAGEN, May 20 (Reuters) - Novo Nordisk on Wednesday rejected claims by Baxter International that its drug used substances developed by the U.S. rival, following the launch this week of a U.S. investigation into possible patent infringement.

    4. Novo Nordisk rejects Baxter patent claim over Novoeight

      Headlines

      Wed, 20 May 2015

      COPENHAGEN, May 20 (Reuters) - Novo Nordisk said on Wednesday it rejected claims by U.S. rival Baxter International that it had infringed patents on drugs to treat the bleeding disorder haemophilia,...

    5. UPDATE 1- Baxter buys cancer drugs from Italian drugmaker for $900 mln

      Headlines

      Tue, 12 May 2015

      May 12 (Reuters) - Baxter International Inc said it agreed to buy two drugs to treat a rare form of blood cancer from Italian drugmaker Sigma-Tau Finanziaria SpA for $900 million, before...

    6. Baxter buys cancer drugs from Italian drugmaker for $900 mln

      Headlines

      Tue, 12 May 2015

      May 12 (Reuters) - Baxter International Inc said it agreed to buy Italian drugmaker Sigma-Tau Finanziaria SpA's portfolio of drugs to treat rare forms of blood cancer for $900 million, before expenses.

    7. Sterile Medical Packaging market in the US Will Reach At CAGR of 7.23% Between 2015-2019

      Commentary

      Thu, 2 Apr 2015

      Copy Of This Report: http://www.marketresearchreports.biz/sample/sample/257250 Key Vendors Amcor Baxter International Bemis Cardinal Health DuPont Other Prominent Vendors 3M Company Ahlstrom Alcan Alcoa Barger Becton, Dickinson and

    8. Health Care: 3 Picks in a More Expensive Sector

      Headlines

      Wed, 1 Apr 2015

      including Merck MRK, Actavis ACT, and Baxter BAX . Even though several years have ..... Value Uncertainty Consider Buying Baxter $84 Wide Low $67.20 Elekta SEK ..... 55.20 Data as of 3-26-15 Baxter BAX Although competition is increasing

    9. From Barron’s, March 9, 2015 (Part 1)

      Commentary

      Sat, 7 Mar 2015

      AAPL ] joins the DJIA and AT&T [ T ] is booted out. Baxter International [ BAX ; yield 3%; fwd EV/EBITDA 10.4] is attractive ..... upcoming split into two – medical-products [to retain Baxter name] and biopharma [to be called Baxalta ]. Steakhouse

    10. Pfizer's Acquisition of Hospira Strengthens Its Moat at a Fair Price

      Headlines

      Thu, 5 Feb 2015

      half of 2015). Pfizer is gaining specialty injectable pharmaceuticals (68% of Hospira sales), which should strengthen ..... the infusion pump market, such as Fresenius SE FMS or Baxter BAX , could be interested in taking the device segment off

    « Prev12345Next »
    Content Partners